|
Nelfinavir
resources
|
|
|
|
|
|
DRUG INFO
Nelfinavir
Drug Name:
Nelfinavir
Indication: For the treatment of HIV infection.
Pharmacology: Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mechanism Of Action: Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Drug Category: Anti-HIV Agents; HIV Protease Inhibitors; ATC:J05AE04
Brand Names/Synonyms: 1UN; AG1346; NELFINAVIR MESYLATE AG1343; NFV; NLF; Nelfinavir; Nelfinavir Mesylate; Nelfinavir [Inn:Ban]; Viracept
Dosage Forms: Tablets, Oral powder
Absorption: Well absorbed
Interactions: DRUG INTERACTIONS
Nelfinavir is an inhibitor of CYP3A (cytochrome P450 3A). Coadministration of VIRACEPT and
drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers) may
result in increased plasma concentrations of the other drug that could increase or prolong
both its therapeutic and adverse effects. Nelfinavir is metabolized in proof by C.P.A.
Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma
concentrations and reduce its therapeutic effect. Coadministration of VIRACEPT and drugs that
inhibit CYP3A may increase nelfinavir plasma concentrations.
Based on known metabolic profiles, clinically significant drug interactions are not expected
between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin,
itraconazole or fluconazole.
Drugs That Should Not Be Coadministered With VIRACEPT
Antiarrhythmics: amiodarone, quinidine
Antihistamines: astemizole, terfenadine
Antimigraine: ergot derivatives
Antimycobacterial agents: rifampin
Benzodiazepines midazolam, triazolam
GI motility agents: cisapride
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT
Antimycobacterial agents: rifabutin
Other Potentially Clinically Significant Drug Interactions With VIRACEPT*
Anticonvulsants: carbamazepine, phenobarbital, phenytoin May decrease nelfinavir plasma concentrations**
Anti-HIV protease inhibitors: indinavir, ritonavir May increase nelfinavir plasma concentrations
Oral contraceptives: ethinyl estradiol, norethindrone Plasma concentrations may be decreased by VIRACEPT
* This table is not all inclusive
** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients
taking these agents concomitantly
Antihistamines
Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged
terfenadine in plasma; therefore, VIRACEPT should not be administered concurrently with terfenadine
because of the potential for serious and/or life-threatening cardiac arrhythmias. Because a similar
interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.
Anti-HIV Protease Inhibitors
Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir
plasma AUC and a 51% increase in indinavir plasma A.C. Currently, there are no safety and efficacy
data available from the use of this combination.
Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir
plasma AUC and very little change in ritonavir plasma A.C. Currently, there are no safety and efficacy
data available from the use of this combination.
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of
saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold
increase in saquinavir plasma A.C. If used in combination with saquinavir hard gelatin capsules at the
recommended dose of 600 mg tid, no dose adjustments are needed. Currently, there are no safety and efficacy
data available from the use of this combination.
Antifungal Agents
Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir
plasma A.C. This change was not considered clinically significant and no dose adjustment is needed when
ketoconazole and VIRACEPT are coadministered.
Anti-HIV Reverse Transcriptase Inhibitors
Didanosine: It is recommended that didanosine be administered on an empty stomach; therefore, nelfinavir
should be administered (with food) one hour after or more than two hours before didanosine.
Zidovudine: Coadministration of zidovudine and lamivudine with VIRACEPT resulted in a 35% decrease in
zidovudine plasma A.C. A dose adjustment is not needed when zidovudine is administered with VIRACEPT.
Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered
with lamivudine or stavudine.
Antimycobacterial Agents
Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC
and a 207% increase in rifabutin plasma A.C. It is recommended that the dose of rifabutin be reduced to
one-half the usual dose when administered with VIRACEPT.
Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
VIRACEPT and rifampin should not be coadministered.
Oral Contraceptives
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease
in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations. Alternate or additional
contraceptive measures should be used during therapy with VIRACEPT
Chemical IUPAC Name: 2-[2-hydroxy-3-(3-hydroxy-2-methyl-benzoyl)amino-4-phenylsulfanyl-butyl]-N-tert-butyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxamide
Chemical Formula: C32H45N3O4S
Half Life: 3.5 - 5 hours
Drug Type: Approved Drug
# Accession No: APRD00003
CAS Registry Number: 159989-64-7
|
|
|
|
|
|
Nelfinavir News
(When available)
Novel Drug Pradefovir Mesylate May Emerge as Treatment Option in ... Dec 15, 2005
DG News KOHALA COAST, HI -- December 15, 2005 -- A novel cytochrome, pradefovir mesylate P450 (PDV), might become a viable treatment option for patients with hepatitis ...
Imatinib mesylate is not likely to be effective for patients with ... Dec 21, 2005
RxPG NEWS, By Mayo Clinic, Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal ...
Imatinib mesylate (Gleevec) may not be effective at treating ... Dec 21, 2005
News-Medical.net, Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs ...
Dishman to expand EM capacity to 7.2mt Jan 12, 2006
Business Standard, Dishman Pharmaceuticals plans to increase installed capacity of its Eprosartan Mesylate (EM) plant from 6. MT to 7.2 MT per month to meet the future demand of ...
Oscient Pharmaceuticals Provides Preliminary Revenues for Fourth ... Jan 9, 2006
Genetic Engineering News, ...quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, and ...
Bio-IT Briefs Jan 12, 2006
Bio-IT World, ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec (imatinib mesylate). ...
INNOVIVE Pharmaceuticals Licenses Potent Dual Bcr-Abl/Lyn Kinase ... Jan 5, 2006
Business Wire (press release), 1, 2005), NS-187 is 25 to 55 times more potent than imatinib mesylate (Gleevec(TM)) in vitro, and at least 10 times as effective as imatinib mesylate in ...
Oscient Pharmaceuticals to Present at 24th Annual JPMorgan ... Jan 3, 2006
Genetic Engineering News, CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE(R) (gemifloxacin mesylate) tablets, the ...
Infinity Initiates Phase I Clinical Trial of IPI-504 for Patients ... Jan 10, 2006
PR Newswire (press release), ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec(R) (imatinib mesylate). ...
Effectiveness of Gleevec® Plus Hydroxyurea for Treatment of ... Dec 22, 2005
Cancer Consultants (press release), ...from the University of Pittsburgh, Dulman, Germany, and Duke University have reported that the combination of Gleevec (imatinib mesylate) plus hydroxyurea ...
Pharmaceutical Industry Marketing and Sales Veteran to Lead ... Jan 4, 2006
PharmaLive.com (press release), ...products. He led the launch of Synthon's first branded drug, Pexeva(r) (paroxetine mesylate) into the SSRI depression market. Prior ...
Vaccine for Chronic Myeloid Leukemia Active in Patients with ... Jan 5, 2006
Business Wire (press release), ...of positive interim data for a novel vaccine known as VAX100 for patients with persistent chronic myeloid leukemia (CML) while on imatinib mesylate (Gleevec(R ...
New Pharmaceutical Treatment Options in the Elderly Dec 14, 2005
Medscape (subscription) Gemifloxacin mesylate (Factive). Gemifloxacin mesylate, which is given daily (320 mg for 5 to 7 days), is a new fluoroquinolone ...
Drug questionable in some kidney cancers Dec 22, 2005
United Press International The drug in question, imatinib mesylate, used to treat patients with gastrointestinal stromal cancers, is said not likely to be effective for patients with high ...
Vaccine Shows Promise Against Residual Chronic Myeloid Leukemia Dec 27, 2005
Cancer Consultants (press release), Use of a cancer vaccine after treatment with Gleevec® (imatinib mesylate) may reduce or eliminate residual leukemia in some patients with chronic myeloid ...
Investigational Drug Shows Promise in Gleevec®-Resistent CML Dec 29, 2005
Cancer Consultants (press release), AMN107 has produced treatment responses in some patients with chronic myeloid leukemia (CML) that does not respond to Gleevec® (imatinib mesylate), as well as ...
Treatment with Gleevec® Continues to Show Benefits in CML Dec 28, 2005
Cancer Consultants (press release), ...to updated study results presented at the 47th annual meeting of the American Society of Hematology (ASH), Gleevec® (imatinib mesylate) produces good long ...
Mayo Clinic Finds Kidney Cancer Patients Unlikely to Respond to ... Dec 22, 2005
DG News ROCHESTER, MN -- December 22, 2005 -- Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with ...
Ramoplanin Demonstrates High Activity Against Wide Array of ... Dec 19, 2005
PharmaLive.com (press release), The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ...
Gleevec® plus Hydroxyurea Beneficial for Some Patients with ... Dec 20, 2005
Cancer Consultants (press release), ...to a recent article published in the Journal of Clinical Oncology, the treatment combination consisting of Gleevec (imatinib mesylate) plus hydroxyurea ...
Desatinib Promising for Patients with CML Who Do Not Respond to ... Dec 23, 2005
Cancer Consultants (press release), ...still in clinical trials, is an effective treatment option for patients with chronic myelogenous leukemia (CML) who do not respond to Gleevec (imatinib mesylate ...
Glivec Seeking to Become First Targeted Treatment for Adult ... Dec 13, 2005
PharmaLive.com (press release), December 13, 2005 – Novartis has submitted a marketing authorization application for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate) tablets in ...
Restless Legs Syndrome Fact Sheet Dec 14, 2005
Community Dispatch (press release) Dopamine agonists such as pergolide mesylate, pramipexole, and ropinirole hydrochloride may be effective in some patients and are less likely to cause ...
Cell Genesys Reports Positive Results from Phase 2 Trial of GVAX ... Dec 12, 2005
DG News Nineteen CML patients with molecular evidence of persistent leukemia despite more than 1 year of Gleevec(R) (imatinib mesylate) therapy were treated with GVAX ...
Roche offers help to local manufacturers to produce HIV medicine ... Jan 12, 2006
SocialFunds.com Roche makes its HIV protease inhibitors Invirase and Viracept available at no profit prices for direct supplies from Roche Basel to LDCs and sub-Saharan Africa ...
Roche offers HIV drug expertise to poor nations Jan 12, 2006
MedIndia, Roche said it would make its HIV protease inhibitors Invirase and Viracept available at no-profit prices for direct supplies from Roche Basel to LDCs and sub ...
HIV Drug Resistance Linked to Viral Fitness Jan 12, 2006
MedPage Today, ...of data on individual pharmacokinetic differences. Also, there was only one candidate protease inhibitor, Viracept (nelfinavir).
SGX Pharmaceuticals Announces Executive Appointments Jan 5, 2006
PR Newswire (press release), ...leadership positions at Agouron Pharmaceuticals, Inc., including serving as co-project leader of the HIV Protease project, which identified Viracept(R) for the ...
The 14 Worst Corporate Evildoers Jan 3, 2006
Axis of Logic, In addition to Viagra, Zoloft, Zithromax and Norvasc, Pfizer produces the HIV/AIDS-related drugs Rescriptor, Viracept and Diflucan (fluconazole). ...
|
|
|
